# Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

> **NCT06509568** · PHASE2 · RECRUITING · sponsor: **Zhejiang Cancer Hospital** · enrollment: 92 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **RADIATION:** Neoadjuvant chemoradiotherapy followed by immunotherapy
- **DRUG:** Neoadjuvant chemoimmunotherapy

## Key facts

- **NCT ID:** NCT06509568
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06509568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06509568, "Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06509568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*